SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
VTRS

Viatris Inc (NASDAQ:VTRS)

US · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - Specialty & Generic
$19.63-$0.25 (-1.26%)
 
Market cap
$22.5B
Insider Score
Health Score
Analyst consensus
Listed since
Mar 17, 1980
Market Cap$22.50B+85.7%
Revenue (ttm)$14.73B+4.3%
Net Income-$607.80M+83.5%
EPS-$0.53+82.9%
Shares Out1.15B
PE Ration/a
Forward PE7.07
Dividend$0.48(2.45%)
Ex-Dividend DateNov 23, 2026
Volume9,274,630
Open$19.99
Previous Close$19.88
Day's Range$19.43 - $20.09
52-Week Range$10.39 - $21.20
Beta0.87
AnalystsHold
Price Target$21.00(+6.98%)
Earnings DateFeb 25, 2027

About VTRS

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Address
Robert J. Coury Global Center, Canonsburg, PA, 15317, US
Market Cap
22.50 billion
Employees
30,000
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.09M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy2 Hold0 SellAvg target $20.00 (+1.9%)

4 firms rating VTRS in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From VTRS’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-1.26%
5 Days
-6.03%
1 Month
+6.22%
6 Months
+17.90%
1 Year
+85.71%

$VTRS stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of VTRS by members of U.S. Congress

Gilbert CisnerosHouse / DPurchase$1.00K – $15.00KNov 18, 2025
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KNov 18, 2025
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KNov 17, 2025
Gilbert Ray CisnerosHouse / DSale$1.00K – $15.00KMar 31, 2025
Gilbert CisnerosHouse / DSale$1.00K – $15.00KMar 31, 2025
Gilbert Ray CisnerosHouse / DSale$1.00K – $15.00KMar 30, 2025
Scott FranklinHouse / RSale$1.00K – $15.00KMay 20, 2021
Scott FranklinHouse / RSale$100.00K – $250.00KMay 20, 2021

Recently reported changes in VTRS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by VTRS's directors and management

Net Shares Purchased by Insiders−60k−30k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

VTRS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

VTRS Revenue by Segment or Geography

$8.11BTotal
Brands$2.46B30.35%
Developed Markets Segment$2.22B27.32%
Generics$1.27B15.70%
Emerging Markets Segment$529.10M6.52%
Lipitor$451.90M5.57%
Norvasc$190.20M2.34%
EpiPen Auto-Injectors$155.80M1.92%
Lyrica$114.20M1.41%
Creon$98.10M1.21%
Viagra$94.10M1.16%
Influvac$90.60M1.12%
Zoloft$78.80M0.97%
Yupelri$71.50M0.88%
Celebrex$70.20M0.87%
Effexor$63.90M0.79%
Xalabrands$43.90M0.54%
Xanax$36.60M0.45%
Amitiza$36.40M0.45%
Dymista$35.40M0.44%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New VTRS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to VTRS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in VTRS

VOOVanguard S&P 500 ETF$580.74M
VTIVanguard Morningstar Total Stock Market ETF$548.13M
VBVanguard Morningstar Small-Cap ETF$490.19M
VBRVanguard Morningstar Small-Cap Value ETF$318.62M
IVViShares Core S&P 500 ETF$307.62M
SPYState Street SPDR S&P 500 ETF$278.28M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from VTRS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
78
News & Sentiment
20% of score
72

News check: Multiple analyst upgrades and price target increases, plus completion of Pacira acquisition and corporate recognition, drive predominantly bullish coverage.

Recent Insider Activity

Buys
0
Sells
2
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

ADPVAdaptiv Select ETF5.93%
DUSADavis Select U.S. Equity ETF5.75%
LSEQHarbor Long-Short Equity ETF (LSEQ)5.42%
IHEiShares U.S. Pharmaceuticals ETF4.90%
FTXHFirst Trust Nasdaq Pharmaceuticals ETF4.22%
RULEAdaptive Core ETF3.87%
PJPInvesco Pharmaceuticals ETF3.79%
DWLDDavis Select Worldwide ETF3.74%
MVPAMiller Value Partners Appreciation ETF3.28%
CVSMCresAlta Small and Mid-Cap ETF3.06%
XPHState Street SPDR S&P Pharmaceuticals ETF2.49%
ABIGArgent Large Cap ETF2.48%

Weight is the stock’s share of each fund’s holdings.